Paul, who has worked as a senior executive in the healthcare industry for over 40 years, will play an active role in advising CorTechs Labs on matters including, but not limited to, business development strategy as well as product development and enhancement.
Mirabella is currently president and chief executive officer of Paul J. Mirabella Investments and Consulting, LLC, where he oversees consulting and investments in the medical device industry and medical diagnostics.
He is actively involved in developing imaging solutions to reduce radiation exposure as well as artificial intelligence applications in a range of healthcare sectors, with a current focus in neurology.
Previously, he served as president and CEO of GE Healthcare Global Diagnostic Imaging Business and the Global Services Business.
More recently, he was a key investor in and served as chairman and CEO of Naviscan, Inc., developer of a high resolution, organ-specific PET scanner. He also held four of the original patents in computed tomography.
Paul Mirabella holds a bachelor's of science in aerospace engineering and applied mechanics from the Polytechnic Institute of Brooklyn (now NYU) and a master's in mechanical engineering from the University of Central Florida. He has been a guest lecturer on leadership at the University of California, San Diego Rady School of Management.
CorTechs Labs develops and markets medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice.
EDX Medical to provide molecular profiling services to Astron Health
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees